Denali TherapeuticsDNLI
Recorded

Denali Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 3 minParticipants23

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Laura Hansen, VP Investor Relations.

Laura HansenVP of Investor Relations

Good afternoon, everyone, and thank you for joining us to discuss Denali Therapeutics' third quarter 2026 financial results and business highlights. Earlier today, we issued our press release and filed our quarterly report. The press release and today's presentation are available in the Investor Relations section of our website. Before we begin, on slide two, I would like to remind everyone that today's discussion includes forward-looking statements, including our expectations for fourth quarter AVLAYAH net product revenue and the timing and availability of clinical data and any regulatory submissions. These statements reflect our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and to the cautionary language in today's release and presentation. Denali undertakes no obligation to update these statements except as required by law.

Laura HansenVP of Investor Relations

Joining me today are Ryan Watts, our Chief Executive Officer, Katie Peng, our Chief Commercial Officer, Peter Chin, our Chief Medical Officer and Head of Development, and Alexander Schuth, our Chief Operating and Financial Officer. Ryan will open with our progress this quarter, Katie will cover the AVLAYAH launch, Peter will review the clinical programs, and Alex will discuss our financial results before Ryan opens the Q&A session.

Ryan WattsCEO

Ryan. Slide four. Thanks, Laura, and thank you all for joining us today.

Ryan WattsCEO

This was a defining quarter for Denali, and we are excited to share it with you. I want to start where we always do, with our purpose, transforming life for people living with serious disease. We are focused on making a real difference for children, adults, and families by delivering medicines across the blood-brain barrier and into the brain. In recent weeks, we have spent time with Hunter syndrome families. Hearing directly what this disease asks of their children and what families hope AVLAYAH can offer brings our purpose into focus. Their trust is a responsibility we carry into the launch and into every program we advance. Slide five. It starts with AVLAYAH, but it is bigger than one medicine. For the Hunter syndrome community, AVLAYAH is the first new FDA-approved therapy in nearly 20 years.

Ryan WattsCEO

It is the first FDA-approved medicine of its kind designed to cross the blood-brain barrier through the transferrin receptor, and the first to come from our TransportVehicle platform. That is a milestone for patients and a milestone for our field. AVLAYAH gives Denali something we have worked toward for a long time, a commercial product that shows what our TransportVehicle platform can do. That same delivery capability underpins a broad pipeline across rare and common diseases. Our ambition now is to repeat what we have achieved in Hunter syndrome program after program. Slide six. You can see the breadth of that pipeline here. On the left are rare genetic diseases, including Hunter syndrome, Sanfilippo syndrome type A, FTD-GRN, and Pompe disease. Together, we estimate these diseases affect more than 30,000 people worldwide. On the right are Alzheimer's and Parkinson's disease, which we estimate affect more than 40 million.

Ryan WattsCEO

Different modalities, different diseases, one shared advantage, our ability to deliver medicines across the blood-brain barrier. Today, we will focus on our most advanced enzyme replacement therapies and our Alzheimer's disease programs. Slide seven. Three things define this quarter, and each one moves us forward. First, AVLAYAH delivered $17.8 million in its second full commercial quarter, well ahead of our expectations. Katie will explain the adoption and access behind this result. Second, the phase I/II study of zafinofusp alfa in Sanfilippo syndrome type A has completed the pre-specified treatment duration for the primary endpoint. We are analyzing the data now and working toward a BLA submission in 2027 as we have planned. Third, both Alzheimer's programs are in the clinic, with initial data expected in 2027. Together with readouts in Sanfilippo, FTD-GRN, and Pompe disease, those studies make next year a landmark year for the breadth of our platform.

Ryan WattsCEO

Katie, over to you. Thank you, Ryan.

Katie PengChief Commercial Officer

We are now two full quarters into the AVLAYAH launch. Patient interest, physician engagement, and access are all moving faster than we expected. This has accelerated revenue growth. Let me walk you through what is driving that momentum and why we are so excited about the opportunity ahead. Slide nine. Families, physicians, and payers each have a role in getting a patient onto treatment. This quarter, we made substantial progress with all three. AVLAYAH generated $17.8 million in net product revenue, up almost fivefold from $3.6 million in our first full quarter, and well above the $10 million-$12 million we guided to in August. It is fantastic to hear from families and physicians who tell us that AVLAYAH is making a difference.

Katie PengChief Commercial Officer

We are also seeing payer recognition of AVLAYAH's value, which has translated into an increase from 50% to 70% of commercial lives covered since last quarter. Looking ahead, we expect $30 million-$32 million in the fourth quarter, which would be more than 65% growth over this quarter. Behind those numbers is our priority, helping more eligible families reach treatment. Slide 10. Let me start with families. We estimate about 500 people living with Hunter syndrome in the U.S., of whom roughly 375 are eligible under the current pediatric label. Interest is broad from families of newly diagnosed children and those considering a transition from standard enzyme replacement therapy. One parent and advocate, Jeanette, described what she has seen in her son: "I've seen meaningful changes in our everyday life, including more expressive language." We have heard similar stories from multiple families about their positive experience with AVLAYAH.

Katie PengChief Commercial Officer

This reflects why families are seeking a therapy designed to reach the brain as well as the body.

Katie PengChief Commercial Officer

We believe that AVLAYAH is on its way to becoming the standard of care for Hunter syndrome. Our focus remains on supporting families through their treatment experience and ultimately reaching all eligible families. Slide 11. Turning to physicians, we reached approximately 90% of our targeted healthcare organizations since launch. Before launch, in a survey of 35 physicians, 90% found the AVLAYAH data motivating to prescribe. What we've seen now is action, and treatment centers are leaning in. They are working through prior authorizations, appeals, and infusion readiness alongside families, and that commitment reflects the value they see in treating neurologic manifestations. Slide 12. Access is expanding fast. Commercial coverage increased from more than 50% to more than 70% of lives during this quarter.

Katie PengChief Commercial Officer

20 state Medicaid programs now list AVLAYAH as covered, up from 14 last quarter, and a permanent J-code took effect on October 1, making billing and reimbursement more straightforward for treatment centers. Having policies in place is an important step, and our team is there for every family along the path, from start form to the first infusion and beyond. We work alongside physicians and families at each step, and as those steps become more familiar, we expect that path to get shorter and smoother. Slide 13. Let me tell you why we are so optimistic about what comes next. The launch is ahead of our plan, and we see a long runway for continued growth.

Katie PengChief Commercial Officer

Families are engaged across the eligible pediatric population, physicians are activated and working with their treatment centers to move patients towards infusion, payer access continues to expand, and we now have a J-code to simplify reimbursement. Together, that progress took net product revenue from $3.6 million in the first full quarter to nearly $18 million in the second. This step-up was larger than we anticipated. Let me explain why. Two factors contributed to our progress this quarter. First, payer coverage expanded rapidly. As I mentioned, AVLAYAH is now covered for more than 70% of commercial lives, and 20 state Medicaid plans now list AVLAYAH as covered. Second, the majority of eligible patients from our phase I/II study moved to commercial treatment faster than anticipated. These patients had already reached their target dose, so they contributed meaningfully to revenue right away.

Katie PengChief Commercial Officer

That puts fourth quarter at $30 million-$32 million, and we expect the patient base to keep building from there as new patients start treatment, access processes improve, and doses escalate. I also want to put the broader launch dynamics into context as well. We have described our revenue launch trajectory as an S-shaped curve, with the steep part coming in 2027. Based on what we are seeing today, that inflection is arriving sooner due to the strong launch execution. Some of the growth we expected later has been pulled forward, including the phase I/II patient transitions, so the step-up between these two quarters shouldn't be read as a run rate. Over the next several quarters, we expect revenue to keep growing at a steadier pace as we reach additional families one by one and help each patient through the steps to treatment. The upside of this patient-by-patient approach is persistence.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day